Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease thalassemia
Symptom |iron overload
Sentences 79
PubMedID- 19756955 Hepcidin mutation in a beta-thalassemia major patient with persistent severe iron overload despite chelation therapy.
PubMedID- 21452907 Pharmacoeconomic considerations in treating iron overload in patients with beta-thalassaemia, sickle cell disease and myelodysplastic syndromes in the us: a literature review.
PubMedID- 24919862 Based primarily on the findings of the thalassa (assessment of exjade((r)) in non-transfusion-dependent thalassemia) trial, the approval for deferasirox has recently been expanded to include the management of chronic iron overload in patients with non-transfusion-dependent thalassaemia (ntdt) syndromes.
PubMedID- 21897589 thalassemia leads to variable pituitary iron overload and, thus, hypophyseal damage.
PubMedID- 20450494 The pathophysiology of thalassaemia is associated with iron overload that generates oxygen free radicals and oxidative tissue injury with ocular vessel alterations.
PubMedID- 21071497 Continued improvement in myocardial t2* over two years of deferasirox therapy in beta-thalassemia major patients with cardiac iron overload.
PubMedID- 20813008 Cardiac magnetic resonance (cmr) has replaced all other surrogate measurements in the determination of transfusional cardiac iron overload in patients with thalassaemia major.
PubMedID- 23516830 In this study production levels of interleukins (il)-12 and il-13 were measured by commercial elisa in culture supernatants of mitogen-stimulated peripheral blood mononuclear cells-from 30 non-splenectomized beta-thalassaemia cases with iron overload and 20 age- and sex-matched healthy individuals.
PubMedID- 21733147 Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload.
PubMedID- 23834310 Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with beta-thalassemia major and severe iron burden.
PubMedID- 22089614 thalassaemias with iron overload need iron chelation while those with iron deficiency require iron supplementation or fortification.
PubMedID- 21808992 Taken together, iron overload in patients with beta-thalassaemia major may potentially result in arterial dysfunction via its effects on the quantity and function of epcs.
PubMedID- 26114738 Efficacy of deferasirox (exjade(r)) in modulation of iron overload in patients with beta-thalassemia intermedia.
PubMedID- 25197009 iron overload in beta-thalassemia major (tm) typically results in iron-induced cardiomyopathy, liver disease, and endocrine complications.
PubMedID- 21791471 This study evaluates whether iron overload in patients with beta thalassemia intermedia is associated with morbidity.
PubMedID- 25820920 The deferiprone and deferasirox combination is efficacious in iron overloaded patients with beta-thalassemia major: a prospective, single center, open-label study.
PubMedID- 25616857 A number of studies have reported heterogeneity of iron distribution in subjects with iron overload due to thalassemia .
PubMedID- 21075283 iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
PubMedID- 22933160 Effect of iron overload on endocrinopathies in patients with beta-thalassaemia major and intermedia.
PubMedID- 25801075 Methods and materials: in this quasi-experimental study, serum ferritin levels were evaluated in 32 beta-thalassemia major patients with severe iron overload before and after receiving combined deferasirox (30-40 mg kg(-1) day(-1) ) and deferoxamine (40-50 mg kg(-1) day(-1) ) 2 days a week.
PubMedID- 25988550 Background: mri imaging is an alternative to serum ferritin for assessing iron overload in patients with thalassaemia disease.
PubMedID- 23966105 Authors' conclusions: in the absence of data from randomised controlled trials, there is no evidence to suggest the need for a change in current treatment recommendations; namely that deferiprone is indicated for treating iron overload in people with thalassaemia major when desferrioxamine is contraindicated or inadequate.
PubMedID- 24555000 1 transfusional hemosiderosis in major thalassemia patients leads to iron overload and then iron deposition in some organs.
PubMedID- 25878400 recently reviewed the iron chelating activity of african walnut and wheat grass extracts as to their potential for natural iron removal agents for iron overload associated with thalassemia, which is currently typically treated clinically with desferal.
PubMedID- 26205801 Objectives: 'the aim of this work was to compare the efficacy of different iron chelating agents' in the treatment of ' iron overload in children with beta thalassemia major'.
PubMedID- 24646011 Moreover, chronic conditions associated with ineffective erythropoiesis, such as non-transfusion-dependent thalassaemia (ntdt), may lead to iron overload through increased gut absorption of iron starting in childhood.
PubMedID- 23426199 iron overload in beta-thalassemia intermedia: an emerging concern.
PubMedID- 20711357 The importance of nutritional immunity as it pertains to iron is exemplified by the increased susceptibility to infection of individuals with iron overload due to thalassemia and primary hemochromatosis, two of the most common genetic diseases of humans 3.
PubMedID- 22023452 Although the evidence for the benefits of iron chelation therapy to treat iron overload in patients with thalassaemia is unequivocal and well founded, its use in patients with mds remains controversial because of a lack of definitive evidence documenting its benefits (10).

Page: 1 2